Allogeneic peripheral blood stem cell transplantation for active hemophagocytic lymphohistiocytosis.
Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation. Successful allogeneic BMT is the only therapy that has produced long-term disease-free survival. However, for patients with active HLH the outcome of BMT remains poor when compared with those transplanted in remission. We describe a patient with active, recurrent HLH treated with high-dose chemotherapy and related allogeneic peripheral blood stem cell (PBSC) transplantation. Hematologic recovery was rapid and the post-transplant course was uncomplicated. The patient is alive and well 2 1/2 years after transplant. Allogeneic PBSC transplantation may deserve further evaluation as an alternative source of stem cells for transplantation in patients with active HLH.
Chan
K W
KW
Department of Pediatrics, Anderson Cancer Center, Houston, TX 77030, USA.
Mullen
C A
CA
Korbling
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006085:Graft Survival; D018380:Hematopoietic Stem Cell Transplantation; D015616:Histiocytosis, Non-Langerhans-Cell / Q000628:therapy*; D006801:Humans; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous